Alps Advisors Inc. raised its holdings in Paratek Pharmaceuticals, Inc. (NASDAQ:PRTK) by 10.2% during the third quarter, according to its most recent disclosure with the Securities and Exchange Commission. The institutional investor owned 27,339 shares of the specialty pharmaceutical company’s stock after buying an additional 2,530 shares during the period. Alps Advisors Inc. owned about 0.10% of Paratek Pharmaceuticals worth $686,000 as of its most recent filing with the Securities and Exchange Commission.

Other institutional investors have also added to or reduced their stakes in the company. Cadence Capital Management LLC bought a new position in shares of Paratek Pharmaceuticals in the second quarter valued at $562,000. Royce & Associates LP lifted its stake in shares of Paratek Pharmaceuticals by 113.3% in the second quarter. Royce & Associates LP now owns 282,900 shares of the specialty pharmaceutical company’s stock valued at $6,818,000 after buying an additional 150,300 shares in the last quarter. Marshall Wace LLP bought a new position in shares of Paratek Pharmaceuticals in the second quarter valued at $942,000. Russell Investments Group Ltd. lifted its stake in shares of Paratek Pharmaceuticals by 481.5% in the second quarter. Russell Investments Group Ltd. now owns 63,787 shares of the specialty pharmaceutical company’s stock valued at $1,538,000 after buying an additional 52,818 shares in the last quarter. Finally, Bank of New York Mellon Corp lifted its stake in shares of Paratek Pharmaceuticals by 17.5% in the first quarter. Bank of New York Mellon Corp now owns 84,045 shares of the specialty pharmaceutical company’s stock valued at $1,618,000 after buying an additional 12,505 shares in the last quarter. 82.46% of the stock is currently owned by hedge funds and other institutional investors.

Paratek Pharmaceuticals, Inc. (PRTK) traded down $1.52 on Wednesday, hitting $20.13. 1,042,700 shares of the company were exchanged, compared to its average volume of 594,135. The company has a debt-to-equity ratio of 0.49, a quick ratio of 10.53 and a current ratio of 10.53. Paratek Pharmaceuticals, Inc. has a one year low of $12.55 and a one year high of $29.00.

A number of research firms have weighed in on PRTK. BidaskClub raised shares of Paratek Pharmaceuticals from a “hold” rating to a “buy” rating in a research note on Thursday, August 10th. Raymond James Financial, Inc. reaffirmed a “strong-buy” rating and issued a $36.00 price objective on shares of Paratek Pharmaceuticals in a research note on Thursday, August 24th. Zacks Investment Research lowered shares of Paratek Pharmaceuticals from a “hold” rating to a “sell” rating in a research note on Wednesday, October 11th. Cantor Fitzgerald reissued an “overweight” rating on shares of Paratek Pharmaceuticals in a research report on Tuesday, August 8th. Finally, ValuEngine lowered shares of Paratek Pharmaceuticals from a “hold” rating to a “sell” rating in a research report on Monday, September 18th. One analyst has rated the stock with a sell rating, two have assigned a hold rating, six have given a buy rating and one has given a strong buy rating to the stock. The company presently has a consensus rating of “Buy” and a consensus price target of $40.00.

ILLEGAL ACTIVITY NOTICE: This news story was first posted by Daily Political and is the sole property of of Daily Political. If you are reading this news story on another publication, it was illegally copied and reposted in violation of United States & international trademark and copyright laws. The legal version of this news story can be viewed at https://www.dailypolitical.com/2017/11/15/alps-advisors-inc-acquires-2530-shares-of-paratek-pharmaceuticals-inc-prtk.html.

Paratek Pharmaceuticals Profile

Paratek Pharmaceuticals, Inc is a clinical-stage biopharmaceutical company. The Company is focused on the development and commercialization of therapeutics based upon tetracycline chemistry. Its product candidates are the antibacterials omadacycline and sarecycline. Omadacycline is an antibiotic being developed for use as an empiric monotherapy option for patients suffering from serious, community-acquired bacterial infections.

Institutional Ownership by Quarter for Paratek Pharmaceuticals (NASDAQ:PRTK)

Receive News & Ratings for Paratek Pharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Paratek Pharmaceuticals Inc. and related companies with MarketBeat.com's FREE daily email newsletter.